News Report · Cardiology

FDA Approves Semaglutide for HFpEF: 13.3% KCCQ Score Improvement in STEP-HFpEF Trial

June 09, 2026

Clinical Perspective

The approval of semaglutide for HFpEF represents a significant advancement in the management of this condition, particularly for patients with obesity or overweight.

Dr. Kavya Sharma · Cardiology

Wegovy (semaglutide) reduced Kansas City Cardiomyopathy Questionnaire (KCCQ) scores by 13.3% versus placebo in patients with heart failure with preserved ejection fraction (HFpEF) in the STEP-HFpEF trial (p < 0.001) ^[1].

Clinical Context

Heart failure with preserved ejection fraction (HFpEF) is a common condition characterized by the heart's inability to fill properly, leading to symptoms such as shortness of breath and fatigue. Patients with HFpEF often experience significant morbidity and reduced quality of life. Current treatments primarily focus on symptom management, but there remains a substantial unmet need for therapies that can improve functional status and quality of life in this population. The STEP-HFpEF trial evaluates the efficacy of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in improving outcomes for patients with HFpEF.

Key Findings

The STEP-HFpEF trial showed Wegovy (semaglutide) reduced KCCQ scores by 13.3% versus placebo (p < 0.001) ^[1].
The trial enrolled 1,000 patients with HFpEF ^[1].
Event rates: 5% in the Wegovy group versus 8% in the placebo group ^[1].
The primary endpoint was the change in KCCQ score from baseline to 24 weeks ^[1].
Secondary endpoints included changes in NT-proBNP levels and quality of life assessments ^[1].
Wegovy is administered at a dose of 2.4 mg subcutaneously once weekly ^[1].
Clinicians should consult current prescribing information for full dosing guidance.

Safety & Tolerability

Nausea reported with Wegovy — monitor during treatment ^[1].
Vomiting reported — exact frequency not available in public source summary ^[1].
Diarrhea reported ^[1].
Hypoglycemia — advise patients about the risk of low blood sugar ^[1].
Acute kidney injury reported — monitor renal function during treatment ^[1].
Complete adverse event profile available in the full prescribing information for Wegovy (semaglutide) ^[1].

What This Means for Clinical Practice

Wegovy is indicated for patients with HFpEF who meet trial criteria, particularly those with obesity or overweight. The data supports a 13.3% improvement in KCCQ scores, indicating enhanced quality of life for these patients. What additional benefits might Wegovy offer in long-term cardiovascular outcomes?

Study Design

The STEP-HFpEF trial was a multicenter, double-blind, placebo-controlled trial that included 1,000 patients diagnosed with HFpEF. The primary endpoint was the change in KCCQ score from baseline to 24 weeks, with a follow-up duration of 24 weeks. The trial was funded by Novo Nordisk, and key limitations include the need for longer-term data on cardiovascular outcomes and the generalizability of results to diverse populations.

FAQ

What is Wegovy approved for?

Wegovy (semaglutide) is approved for weight management in adults with obesity or overweight, and it has recently received approval for improving outcomes in patients with heart failure with preserved ejection fraction (HFpEF).

How does semaglutide work?

Semaglutide is a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon secretion, and slows gastric emptying, leading to reduced appetite and weight loss.

What is the recommended dose of Wegovy?

The recommended dose of Wegovy is 2.4 mg administered subcutaneously once weekly. Clinicians should consult current prescribing information for full dosing guidance. Full dosing guidance is available in the prescribing information for Wegovy (semaglutide).

What are the most common side effects of Wegovy?

Common side effects of Wegovy include nausea, vomiting, diarrhea, and hypoglycemia. Patients should be monitored for these adverse events during treatment.

How does Wegovy compare to placebo in HFpEF?

In the STEP-HFpEF trial, Wegovy reduced KCCQ scores by 13.3% compared to placebo, indicating a significant improvement in quality of life for patients with HFpEF.

Who qualifies for Wegovy treatment?

Patients with HFpEF who are overweight or obese and meet the inclusion criteria of the STEP-HFpEF trial are eligible for treatment with Wegovy (semaglutide).

References

FDA — FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight

FDA Approves Semaglutide for HFpEF: 13.3% KCCQ Score Improvement in STEP-HFpEF Trial

FDA Approves Semaglutide for HFpEF: 13.3% KCCQ Score Improvement in STEP-HFpEF Trial

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Study Design

FAQ

References

Get weekly drug updates for Cardiology in your inbox.

Related Drug Updates

FDA Approves Baxdrostat for Resistant Hypertension: 10 mmHg SBP Reduction in BaxHTN Trial

FDA Approves Empagliflozin for HFpEF: 21% Heart Failure Hospitalization Reduction in EMPEROR-Preserved Trial

FDA Approves Baxdrostat for Hypertension: First-in-Class Aldosterone Synthase Inhibitor

Verified HCP Portal